Analyst firms · Barclays · QGEN

Barclays QGEN price target and rating history

Qiagen N.V. (QGEN) · Health Care

Barclays rates Qiagen N.V. (QGEN) Overweight with a $55 price target, as of its latest action on Oct 6, 2026. It has published 3 rating actions on QGEN since June 2025, including 1 upgrade and 1 downgrade. Across 8 firms with a QGEN price target in the last 12 months, the median target is $46.25. Barclays's $55 is 19% above that.

Current rating
Overweight
Price target
$55
Median target, all firms
$46.25
Actions on QGEN
3

Barclays price target on QGEN

$55$50$442026
Barclays price target on QGEN, each point a stated target, June 2025 to October 2026.

Every Barclays rating on QGEN

How other firms rate QGEN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysOverweight$55Oct 6, 2026
UBSNeutral$47Sep 9, 2026
BerenbergHold$45.50Jul 14, 2026
Kepler CheuvreuxHold$38.60Jun 25, 2026
Morgan StanleyOverweight$42Jun 23, 2026
Robert W. BairdOutperform$43Apr 29, 2026
Deutsche BankBuy$54Mar 13, 2026
CitigroupNeutral$50Dec 11, 2025

Questions about Barclays and QGEN

What is Barclays's price target for QGEN?
Barclays's latest stated price target for Qiagen N.V. (QGEN) is $55, from its action on Oct 6, 2026.
What is Barclays's rating on QGEN?
Barclays rates QGEN Overweight, a bullish rating, as of Oct 6, 2026.
When did Barclays last change its view on QGEN?
On Oct 6, 2026, Barclays upgrades to Overweight from Equal Weight, price target $55.
How does Barclays's QGEN target compare with other analysts?
Across 8 firms with a QGEN price target in the last 12 months, the median target is $46.25. Barclays's $55 is 19% above that.

More QGEN rating histories

All Barclays ratingsQGEN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.